Literature DB >> 11564368

Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

L M Pachman1, T O Fedczyna, T S Lechman, J Lutz.   

Abstract

Little is known concerning factors associated with the outcome of juvenile dermatomyositis (JDM), which can be variable and lethal. Previous work has documented that the association of DQA1*0501 with JDM is higher than in control groups and that the first symptoms (rash and weakness) of JDM appear to follow evidence of an infectious process--most frequently upper respiratory in nature. Preliminary data show that a long period of symptoms being left untreated before starting therapy and the TNF alpha-308A allele are associated with prolonged JDM symptoms requiring > or = 36 months of immunosuppressive therapy. A short duration of untreated disease is associated with a relative increase in CD8(+) T cells and CD56(+) natural killer (NK) cells in the untreated JDM muscle biopsy compared with a longer duration of untreated disease. The TNF alpha-308A allele is overrepresented in white children with JDM. In addition, it is associated with pathologic calcifications, increased production of TNF alpha by peripheral blood mononuclear cells in vitro and JDM muscle fibers in vivo, and occlusion of capillaries, which may be mediated in part by elevated circulating levels of thrombospondin-1, a potent anti-angiogenic factor. We speculate that DQA1*0501 is associated with JDM susceptibility to an infectious process, eliciting and activating NK cells early in the disease course. We conclude that the TNF alpha-308A allele indicates directly (or is a surrogate marker of) children with JDM who produce higher concentrations of TNF alpha in response to this undefined inflammatory stimulus, as well as increased concentrations of TSP-1 with resultant small vessel occlusion, contributing to subsequent disease chronicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564368     DOI: 10.1007/s11926-996-0007-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  43 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Cutting edge: persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: implications in autoimmunity.

Authors:  N C Lambert; P C Evans; T L Hashizumi; S Maloney; T Gooley; D E Furst; J L Nelson
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

3.  Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis.

Authors:  S Roux; H P Seelig; O Meyer
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

Review 4.  Juvenile dermatomyositis presenting with rash alone.

Authors:  D M Eisenstein; A S Paller; L M Pachman
Journal:  Pediatrics       Date:  1997-09       Impact factor: 7.124

5.  Clinical significance of specific autoantibodies in juvenile dermatomyositis.

Authors:  B M Feldman; M Reichlin; R M Laxer; I N Targoff; L D Stein; E D Silverman
Journal:  J Rheumatol       Date:  1996-10       Impact factor: 4.666

6.  Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.

Authors:  A E Koch; Z Szekanecz; J Friedman; G K Haines; C B Langman; N P Bouck
Journal:  Clin Immunol Immunopathol       Date:  1998-02

7.  Influence of TNF microsatellite polymorphisms (TNFa) on age-at-onset of insulin-dependent diabetes mellitus.

Authors:  H Obayashi; N Nakamura; M Fukui; H Tegoshi; M Fujii; M Ogata; G Hasegawa; H Shigeta; Y Kitagawa; K Nakano; M Kondo; I Fukui; E Maruya; H Saji; M Ohta; M Nishimura
Journal:  Hum Immunol       Date:  1999-10       Impact factor: 2.850

8.  Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression.

Authors:  M C Knuchel; T J Spira; A U Neumann; L Xiao; D L Rudolph; J Phair; S M Wolinsky; R A Koup; O J Cohen; T M Folks; R B Lal
Journal:  AIDS Res Hum Retroviruses       Date:  1998-03-01       Impact factor: 2.205

9.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein.

Authors:  G Cambridge; E Ovadia; D A Isenberg; V Dubowitz; J Sperling; R Sperling
Journal:  Clin Exp Rheumatol       Date:  1994 Jul-Aug       Impact factor: 4.473

View more
  14 in total

1.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 2.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

3.  Dysregulated NK cell PLCγ2 signaling and activity in juvenile dermatomyositis.

Authors:  Allison A Throm; Joshua B Alinger; Jeanette T Pingel; Allyssa L Daugherty; Lauren M Pachman; Anthony R French
Journal:  JCI Insight       Date:  2018-11-15

4.  TNFα induces inflammatory stress response in microvascular endothelial cells via Akt- and P38 MAP kinase-mediated thrombospondin-1 expression.

Authors:  Arwa Fairaq; Anna Goc; Sandeep Artham; Harika Sabbineni; Payaningal R Somanath
Journal:  Mol Cell Biochem       Date:  2015-05-12       Impact factor: 3.396

Review 5.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 6.  Cutaneous dermatomyositis in the era of biologicals.

Authors:  Natalie A Wright; Ruth Ann Vleugels; Jeffrey P Callen
Journal:  Semin Immunopathol       Date:  2015-11-12       Impact factor: 9.623

Review 7.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

8.  Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis.

Authors:  Katherine E Lintner; Anjali Patwardhan; Lisa G Rider; Rabheh Abdul-Aziz; Yee Ling Wu; Emeli Lundström; Leonid Padyukov; Bi Zhou; Alaaedin Alhomosh; David Newsom; Peter White; Karla B Jones; Terrance P O'Hanlon; Frederick W Miller; Charles H Spencer; Chack Yung Yu
Journal:  Ann Rheum Dis       Date:  2015-10-22       Impact factor: 19.103

Review 9.  Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2011-01-21       Impact factor: 6.682

Review 10.  New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.

Authors:  Alexandra Maria Giovanna Brunasso; Werner Aberer; Cesare Massone
Journal:  ScientificWorldJournal       Date:  2014-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.